Puerperal vulvar edema and hematoma complicated by overuse of cold therapy­a report of two cases.

BACKGROUND: Puerperal vulvar edema and hematoma are rare complications of the postpartum period. The two conditions have similar risk factors and are known to occur together. The outcome of vulvar edema or hematoma is typically favorable, as both reabsorb with local perfusion mechanisms. Management recommendations vary, with recommendations based on limited evidence and anecdotal experience. CASES: We report two cases, one of puerperal vulvar edema and one of puerperal vulvar hematoma, which became complicated by overuse of cold therapy during conservative management. CONCLUSIONS: In both cases, initial conservative management failed. The common aspect was the overuse of ice packs directly applied to the perineum for comfort. Although studies indicate cold therapy should be applied to the perineum immediately postpartum for best pain relief results, there are no evidence-based indications for the duration of treatment. This report should serve to alert providers of the potential complication of excessive and prolonged ice application. We suggest clarification of conservative management to include the following: apply cool gel packs in short intervals, use cold therapy only within the first 24 to 48 hours postpartum, and no direct application of ice therapy.

Determination of genetic predisposition to patent ductus arteriosus in preterm infants.

OBJECTIVE: Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to approximately 70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants. METHODOLOGY: We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles. RESULTS: P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 beta and tumor necrosis factor receptor-associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population. CONCLUSIONS: Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.